抗生素诱发获得性凝血因子Ⅴ抑制物1例并文献复习

doi:10.3969/j.issn.1004-583X.2026.01.010

摘要/Abstract

摘要：

目的探讨抗生素诱发的获得性凝血因子Ⅴ抑制物患者的临床特征。方法报告1例抗生素相关的获得性凝血因子Ⅴ抑制物患者的临床特征、实验室检查、诊治经过及转归,并进行相关文献复习和讨论。结果患者年龄84岁,无遗传性凝血因子缺乏病史,因肺炎应用抗生素后出现凝血因子Ⅴ抑制物滴度升高。结论获得性凝血因子Ⅴ抑制物所致凝血障碍是一种少见疾病,抗生素的使用是其常见的一种诱发因素。

关键词: 血液凝固障碍, 获得性凝血因子Ⅴ抑制物, 抗生素

Abstract:

Objective To investigate the clinical characteristics of patients with antibiotic associated acquired factor Ⅴ inhibitor (AFⅤI). Methods We describe the clinical presentation, laboratory findings, diagnostic and therapeutic course, and outcome of a patient with antibiotic-associated AFⅤI, and we review and discuss relevant literature. Results An 84-year-old patient without a history of hereditary coagulation factor deficiency developed elevated levels of FV inhibitor after receiving antibiotics for pneumonia. Conclusion AFⅤI-related coagulopathy is a rare disorder, and exposure to antibiotics is a common precipitating factor.

Key words: blood coagulation disorders, acquired factor V inhibitors, antibiotics

中图分类号:

R554

任喜艳, 马丽云, 任冠军, 薛旗山, 闫春良, 景淑贤. 抗生素诱发获得性凝血因子Ⅴ抑制物1例并文献复习[J]. 临床荟萃, 2026, 41(1): 60-63.

Ren Xiyan, Ma Liyun, Ren Guanjun, Xue Qishan, Yan Chunliang, Jing Shuxian. Antibiotic-associated acquired factor Ⅴ inhibitor: A case report and literature review[J]. Clinical Focus, 2026, 41(1): 60-63.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.01.010

https://www.lchc.cn/CN/Y2026/V41/I1/60

图/表 2

图1 凝血功能相关指标及相应处理方式注:红色直线表示该项目的参考值上限,黑色直线表示该项目的参考值下限。①处理方式:2月18日:血浆+维生素K; ②2月19-21日:血浆+人凝血酶原复合物+维生素K;③2月22日: 血浆+维生素K; ④2月23-24日:血浆+人凝血酶原复合物+维生素K;⑤2月25日-3月1日甲泼尼龙40 mg每日1次静脉点滴;⑥3月2日:血浆+人凝血酶原复合物+止血药物; ⑦3月3-6日:止血药物;⑧3月7日自动出院;⑨同年6月11日再次入院。

Fig.1 Coagulation function related indicators and treatment methods

表1 凝血因子检测结果

Tab.1 Detection results of coagulation factors

项目	结果(%)
凝血因子Ⅱ	10.4 ↓
凝血因子Ⅶ	64.7
凝血因子Ⅶ	47.7 ↓
凝血因子Ⅸ	49.7 ↓
凝血因子Ⅹ	58.5
凝血因子Ⅻ	30.9 ↓
凝血因子Ⅺ	34.4 ↓
凝血因子Ⅴ	0.1 ↓ ↓

参考文献 21

[1]	Yamada S, Asakura H. Acquired factor V inhibitor[J]. Rinsho Ketsueki, 2020, 61(7):791-798. doi: 10.11406/rinketsu.61.791.
[2]	Wang IE, Copper G, Moussa SA. Diagnostic approaches for COVID-19 and its associated complications[J]. Diagnostics (Basel), 2021, 11(11):2071.doi: 10.3390/diagnostics11112071.
[3]	Franchini M, Lippi G. Acquired factor V inhibitors: A systematic review[J]. J Thromb Thrombolysis, 2011, 31(4):449-457.doi: 10.1007/s11239-010-0529-6.
[4]	王栋, 谢妍, 梁佩淇, 等. 新型冠状病毒感染后获得性凝血因子Ⅴ抑制物患者1例报告并文献复习[J]. 血栓与止血学, 2024, 30(3):121-124.doi:10.3969/j.issn.1009-6213.2024.03.005.
[5]	Chartier AR, Hillert CJ, Gill H, et al. Acquired factor Ⅴ inhibitor after antibiotie therapy: A clinical case report and review of the literature[J]. Cureus, 2020, 12(7):e9481.doi:10.7759/cureus.9481.
[6]	王为, 华宝来, 范连凯, 等. 获得性因子V抑制物3例报道及文献复习[J]. 血栓与止血学, 2011, 17(6):275-277.doi:10.3969/j.issn.1009-6213.2011.06.009.
[7]	Segers K, Dahlbiick B, Nicolaes GA. Coagulation factor V andthrombophilia: Background and mechanisms[J]. Thromb Haemost, 2007, 98(3): 530-542.
[8]	Ortel TL, Quinn-allen MA, Charles LA, et al. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity[J]. J Clin Invest, 1992, 90(6):2340-2347. doi: 10.1172/JCI116123.
[9]	Nakata K, Ueda S, Matsunaga H, et al. High titer of acquired factor V inhibitor presenting with a pseudo-deficiency of multiple coagulation factors[J]. Intern Med, 2018, 57:393-397.doi: 10.2169/internalmedicine.9150-17.
[10]	王甜甜, 房云海, 王杰, 等. 凝血因子Ⅴ抑制物致多项凝血因子活性假性降低[J]. 临床检验杂志, 2021, 39(8):605-606+613.doi:10.13602/j.cnki.jcls.2021.08.10.
[11]	Knobl P, Lechner K. Acquired factor V inhibitors[J]. Baillieres Clin Haematol, 1998, 11(2):305-318. doi:10.1016/s0950-3536(98)80050-4.
[12]	Kinjo Y, Yoshimura K, Suzuki T, et al. Development of asymptomatic acquired factor V inhibitor after the administration of antibiotics[J]. Rinsho Ketsueki, 2014, 55(11):2311-2315.
[13]	Cui QY, Shen HS, Wu TQ, et al. Development of acquired factor V inhibitor after treatment with ceftazidime: A case report and review of the literature[J]. Drug Des Devel Ther, 2015, 24:9:2395-2398. doi: 10.2147/DDDT.S68682.
[14]	Taniwaki M, Katsutani S, Yamasaki M, et al. Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: A case report[J]. Ann Hematol, 2019, 98(8):1989-1990.doi: 10.1007/s00277-019-03638-6.
[15]	李佳菀, 谢文慧, 周双, 等. 头孢他啶阿维巴坦致凝血酶原时间延长一例[J]. 临床药物治疗杂志, 2023, 21(5):90-92.doi:10.3969/j.issn.1672-3384.2023.05.017.
[16]	Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2):239-245. doi: 10.1038/clpt.1981.154.
[17]	Ang AL, Kuperan P, Ng CH, et al. Acquired factor V inhibitor. A problem-based systematic review[J]. Thromb Haemost, 2009, 101(5):852-859.
[18]	Yamada Y, Miyakawa Y, Sawano M, et al. Successful treatment of severe lung hemorrhage caused by acquired factor V inhibitor with rituximab[J]. Intern Med, 2014, 53: 1083-1085.doi: 10.2169/internalmedicine.53.1552.
[19]	Wang X, Qin X, Yu Y, et al. Acquired factor V deficiency in a patient with a urinary tract infection presenting with haematuria followed by multiple haemorrhages with an extremely low level of factor V inhibitor: A case report and review of the literature[J]. Blood Coagul Fibrinolysis, 2017, 28(4):334-341.doi: 10.1097/MBC.0000000000000581.
[20]	Mima F, Minami R, Asako M, et al. Acquired factor V inhibitor complicated with immune thrombocytopenia[J]. Intern Med, 2022, 61(1):91-95.doi: 10.2169/internalmedicine.7173-21.
[21]	Goulenok T, Vasco C, Faille D, et al. Acquired factor Vinhibitor:A nation-wide study of 38 patients[J]. Br J Haematol, 2021, 192(5):892-899.doi: 10.1111/bjh.17308.